AstraZeneca stock heads into the open after a 1.2% New York drop
Published on 09/16/2026 at 07:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock closed at USD 161.76 on the New York Stock Exchange on September 15, 2026, down 1.24% from the previous session, according to MarketBeat data based on NYSE pricing. The move left the shares trailing the broader US market, with the S&P 500 little changed over the same session.
September 15, 2026 in numbers
AstraZeneca plc (ISIN US6549022043, NYSE: AZN) saw its US-listed shares end the September 15, 2026 session at USD 161.76 on the New York Stock Exchange after trading within a daily range around USD 159 to USD 164, per closing data reported by MarketBeat. The 1.24% decline contrasted with a relatively stable S&P 500 close, so AstraZeneca underperformed the benchmark on the day. London-listed AstraZeneca shares were marked down as well, with MarketBeat noting a London price near 120.90 GBP on September 15, 2026, while finanzen.ch reported a late afternoon quote of 120.24 GBP with a 1.1% loss in London trading on September 15, 2026.finanzen.ch MarketBeat data indicated a recent market capitalization derived from a price of USD 161.76 as of September 15, 2026, placing AstraZeneca comfortably within the large-cap pharma peer group.MarketBeat
Beyond price action, sentiment around AstraZeneca was influenced by fresh analyst commentary and insider transactions. Investing.com reported on September 15, 2026 that Deutsche Bank upgraded AstraZeneca from Sell to Hold and raised its London price target to GBP 117.00 from GBP 115.00, citing updated views following recent trial developments.Investing.com On the same date, TipRanks highlighted that AstraZeneca chair Michel Demare bought additional shares around GBP 121.21 in London, a transaction disclosed under market abuse rules and signaling ongoing insider confidence.TipRanks These moves framed the backdrop for the stock’s modest decline in the latest completed session.
Outlook today for AstraZeneca stock
Today, AstraZeneca enters the US session with recent analyst revisions and insider buying likely remaining part of the narrative investors consider alongside broader healthcare sector trends. Deutsche Bank’s rating upgrade and revised price target from September 15, 2026 stay in focus as a fresh signal on valuation.Investing.com The disclosed share purchase by chair Michel Demare around GBP 121.21 on September 15, 2026 may also be watched as a governance and confidence signal as the stock heads into today’s trading.TipRanks In the absence of a major scheduled company event within the next few days in the available calendars, AstraZeneca’s shares are set to trade today mainly against the backdrop of these recent signals and general market conditions.
